Prostate Cancer

Latest News


CME Content


Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.

Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.

Six therapies have demonstrated improved survival in metastatic castration-resistant prostate cancer, yet there is insufficient data regarding combination and sequencing of these agents, and predicting response or resistance to them. Prostate cancer patients, researchers, and clinicians alike await the results of key phase III studies in 2017 that could further impact how prostate cancer is managed.